金融界4月11日消息，万泰生物公告称，本次发布对外投资管理制度修订内容，涵盖总则、对外投资的组织机构、审批权限、审批程序、人事管理、回收及转让、财务管理及审计、附则等方面。明确股东大会、董事会为投资的决策机构，规定了不同规模投资的审批标准，如交易涉及资产总额、标的资产净额、成交金额、产生利润等占相应比例和绝对金额的规定，还涉及关联交易、累计计算原则等规定，并对投资的可行性研究、人事管理、回收转让、财务管理审计等方面进行了规范。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.